EAGLE PHARMACEUTICALS INC (EGRX)
Institutional ownership reported to the SEC as of Q2 2026, across 31 quarters.
2
Reporting holders
$8.5K
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| Stanley-Laman Group, Ltd. | $8.0K | 12,000 | 0.00% | 31q | HELD |
| Archer Investment Corp | $470 | 700 | 0.00% | 14q | +100.0% |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2 | $8.5K | 12,700 | 0 | 1 | 0 | 0.0% |
| Q1 2026 | 2 | $4.2K | 12,350 | 0 | 0 | 0 | 0.0% |
| Q4 2025 | 2 | $8.6K | 12,350 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 2 | $33.3K | 12,350 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 2 | $35.8K | 12,350 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 2 | $12.1K | 12,350 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 7 | $26.8K | 53,659 | 0 | 1 | 3 | 0.0% |
| Q3 2024 | 60 | $35.5M | 8,514,459 | 10 | 8 | 26 | 10.5% |
| Q2 2024 | 72 | $75.9M | 11,552,663 | 14 | 11 | 35 | 14.8% |
| Q1 2024 | 84 | $55.3M | 10,517,336 | 14 | 23 | 32 | 0.4% |
| Q4 2023 | 95 | $49.1M | 9,279,920 | 21 | 38 | 20 | 1.1% |
| Q3 2023 | 93 | $145.8M | 9,244,415 | 12 | 26 | 43 | 0.0% |
| Q2 2023 | 106 | $187.1M | 9,618,746 | 9 | 39 | 43 | 0.0% |
| Q1 2023 | 121 | $293.8M | 10,354,549 | 16 | 44 | 46 | 0.0% |
| Q4 2022 | 114 | $279.4M | 9,498,629 | 17 | 46 | 32 | 0.6% |
| Q3 2022 | 151 | $340.7M | 12,751,955 | 18 | 58 | 47 | 1.1% |
| Q2 2022 | 162 | $516.9M | 11,634,041 | 17 | 47 | 69 | 0.0% |
| Q1 2022 | 161 | $557.2M | 11,250,258 | 13 | 52 | 64 | 0.1% |
| Q4 2021 | 163 | $575.8M | 11,294,595 | 18 | 43 | 60 | 0.2% |
| Q3 2021 | 151 | $661.2M | 11,827,780 | 16 | 41 | 59 | 0.2% |
| Q2 2021 | 144 | $516.0M | 12,049,504 | 11 | 50 | 49 | 0.0% |
| Q1 2021 | 154 | $508.4M | 12,187,304 | 13 | 63 | 53 | 0.0% |
| Q4 2020 | 163 | $573.9M | 12,322,767 | 14 | 48 | 66 | 0.0% |
| Q3 2020 | 167 | $542.5M | 12,739,080 | 23 | 63 | 51 | 0.3% |
| Q2 2020 | 163 | $634.4M | 13,193,113 | 17 | 51 | 64 | 0.2% |
| Q1 2020 | 167 | $621.2M | 13,400,588 | 17 | 54 | 58 | 0.7% |
| Q4 2019 | 180 | $832.2M | 13,512,327 | 16 | 51 | 73 | 2.5% |
| Q3 2019 | 183 | $760.9M | 13,340,025 | 17 | 59 | 68 | 0.8% |
| Q2 2019 | 181 | $792.6M | 13,610,287 | 19 | 63 | 49 | 4.4% |
| Q1 2019 | 183 | $744.8M | 14,484,687 | 19 | 51 | 60 | 1.8% |
| Q4 2018 | 180 | $623.9M | 15,172,744 | 2 | 3 | 4 | 1.5% |